



PATENT
Attorney Docket No. UM-08333

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hildebrandt *et al.*
Serial No.: 10/648,512 Group No.: 1641
Filed: 8/26/2003 Examiner: Grun
Entitled: NPHP Nucleic Acids and Proteins

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 24, 2006.

By: 

Mary Ellen Waite


Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

A check for \$180.00 is also enclosed pursuant to 37 C.F.R. § 1.17(p) for filing this Information Disclosure Statement after three months as set forth in C.F.R. § 1.97(c).

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: July 24, 2006


Tanya A. Arenson
Registration No. 47,391

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 305
San Francisco, California 94105
608/218-6900




PATENT
Attorney Docket No. **UM-08333**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Hildebrandt *et al.***
Serial No.: **10/648,512** Group No.: **1641**
Filed: **8/26/2003** Examiner: **Grun**
Entitled: **NPHP Nucleic Acids and Proteins**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- ZEISBERG *et al.*, *Hypertens.* 10:315 [2001]
- SMITH *et al.*, *Am. J. Dis. Child.* 69:369 [1945]
- FANCONI *et al.*, *Helv. Paediatr. Acta.* 6:1 [1951]
- HILDEBRANDT *et al.*, *Nature Genet.* 17:149 [1997]
- AVNER E, Holliday M, Barrat T (eds.) *Pediatric Nephrology*. Williams & Wilkins, Baltimore)
07/27/2006 NNGUYEN1 00000038 10640512
- ANTIGNAC *et al.*, *Nature Genet.* 3:342 [1993] 02 FC:1806 188.00 OP
- HILDEBRANDT *et al.*, *Am J Hum Genet* 53:1256-1261 [1993]

- HAIDER et al. "A Bedouin Kindred with Infantile Nephronophthisis Demonstrates Linkage to Chromosome 9 by Homozygosity Mapping", *Am J Hum Genet* 63:1404-1410 [1998]
- OMRAN et al. "Identification of a New Gene Locus for Adolescent Nephronophthisis on Chromosome 3q22 in a Large Venezuelan Pedigree", *Am J Hum Genet* 66:118-127 [2000]
- WALDHERR et al., *Virchows Arch A Pathol Anat Histol* 394:235-254 [1982]
- SCHUEMANN et al. "Mapping of Gene Loci for Nephronophthisis Type 4 and Senior-Løken Syndrome, to Chromosome 1p36", *Am. J. Hum. Genet.* 70:1240 [2002]
- HILDEBRANDT and Otto, "Molecular Genetics of Nephronophthisis and Medullary Cystic Kidney Disease" *J Am Soc Nephrol* 11:1753-1761 [2000]
- DONALDSON et al., *Exp Cell Res* 256:168-178 [2000]
- BENZING et al. "Nephrocystin interacts with Pyk2, p130(Cas), and tensin and triggers phosphorylation of Pyk2", *Proc Natl Acad Sci USA* 98:9784-9789 [2001]
- DONALDSON et al. "Nephrocystin-conserved Domains Involved in Targeting to Epithelial Cell-Cell Junctions, Interaction with Filamins, and Est" *J Biol Chem* 277:29028-29035 [2002]
- SENIOR et al., *Am J Ophthalmol* 52:625-633 [1961]
- Løken et al., *Acta Paediatr* 50:177-184 [1961]
- CARIDI et al., *Am J Kidney Dis* 32:1059-1062 [1998]
- DIB et al., *Nature* 380:152 [1996]
- POLAK et al., *Am J Ophthalmol* 95:487-494 [1983]
- NURNBERGER et al. ARPKD and Inversin (inv): Isoforms and Cellular Distributions. *Journal of the American Society of Nephrology*. September 2001, Vol. 12, page 542A, see Abstract # A2810
- NURNBERGER et al. Inversin Forms a Complex with Catenins and N-Cadherin in Polarized Epithelial Cells. *Molecular Biology of the Cell*. September 2002, Vol. 13, No. 9, pages 3096-3106, see entire document.

- MORGAN et al., Nat. Genet. 20, 149 [1998]
- OTTO et al. "Nephrocystin: Gene Expression and Sequence Conservation between Human, Mouse, and Caenorhabditis Elegans", J. Am. Soc. Nephrol. 11:270 [2000]
- GAGNADOUX et al., Pediatr. Nephrol. 3, 50 [1989]
- FILLASTRE et al., Clin Nephrol 5:14-19 [1976]
- MOCHIZUKI et al., Nature 395, 177 [1998]


This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: _____

7/24/06



Tanya A. Arenson
Registration No. 47,391
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/648,512
Filing Date	08/26/03
First Named Inventor	Friedhelm Hildebrand
Art Unit	1641
Examiner Name	GRUN, JAMES LESLIE
Attorney Docket Number	UM-08333

Sheet 1 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	ZEISBERG et al., Hypertens. 10:315 [2001]	
	2	SMITH et al., Am. J. Dis. Child. 69:369 [1945]	
	3	FANCONI et al., Helv. Paediatr. Acta. 6:1 [1951]	
	4	HILDEBRANDT et al., Nature Genet. 17:149 [1997]	
	5	MOCHIZUKI et al., Nature 395, 177 [1998]	
	6	ANTIGNAC et al., Nature Genet. 3:342 [1993]	
	7	HILDEBRANDT et al., Am J Hum Genet 53:1256-1261 [1993]	
	8	HAIDER et al."A Bedouin Kindred with Infantile Nephronophthisis Demonstrates Linkage to Chromosome 9 by Homozygosity Mapping", Am J Hum Genet 63:1404-1410 [1998]	
	9	OMRAN et al."Identification of a New Gene Locus for Adolescent Nephronophthisis on Chromosome 3q22 in a Large Venezuelan Pedigree", Am J Hum Genet 66:118-127 [2000]	
	10	WALDHERR et al., Virchows Arch A Pathol Anat Histol 394:235-254 [1982]	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/648,512
		Filing Date	08/26/03
		First Named Inventor	Friedhelm Hildebrand
		Art Unit	1641
		Examiner Name	GRUN, JAMES LESLIE
Sheet 2 of 3	Attorney Docket Number	UM-08333	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	SCHUEMANN et al. "Mapping of Gene Loci for Nephronophthisis Type 4 and Senior-Løken Syndrome, to Chromosome 1p36", Am. J. Hum. Genet. 70:1240 [2002]	
	12	DIB et al., Nature 380:152 [1996]	
	13	HILDEBRANDT and Otto, "Molecular Genetics of Nephronophthisis and Medullary Cystic Kidney Disease" J Am Soc Nephrol 11:1753-1761 [2000]	
	14	DONALDSON et al., Exp Cell Res 256:168-178 [2000]	
	15	BENZING et al. "Nephrocystin interacts with Pyk2, p130(Cas), and tensin and triggers phosphorylation of Pyk2", Proc Natl Acad Sci USA 98:9784-9789 [2001]	
	16	DONALDSON et al. "Nephrocystin-conserved Domains Involved in Targeting to Epithelial Cell-Cell Junctions, Interaction with Filamins, and Est" J Biol Chem 277:29028-29035 [2002]	
	17	SENIOR et al., Am J Ophthalmol 52:625-633 [1961]	
	18	Løken et al., Acta Paediatr 50:177-184 [1961]	
	19	CARIDI et al., Am J Kidney Dis 32:1059-1062 [1998]	
	20	POLAK et al., Am J Ophthalmol 95:487-494 [1983]	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/648,512
		Filing Date	08/26/03
		First Named Inventor	Friedhelm Hildebrand
		Art Unit	1641
		Examiner Name	GRUN, JAMES LESLIE
Sheet 3	of 3	Attorney Docket Number	UM-08333

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	21	NURNBERGER et al. ARPKD and Inversin (inv): Isoforms and Cellular Distributions. Journal of the American Society of Nephrology. September 2001, Vol. 12, page 542A, see Abstract # A2810	
	22	NURNBERGER et al. Inversion Forms a Complex with Catenins and N-Cadherin in Polarized Epithelial Cells. Molecular Biology of the Cell. September 2002, Vol. 13, No. 9, pages 3096-3106, see entire document.	
	23	MORGAN et al., Nat. Genet. 20, 149 [1998]	
	24	OTTO et al. "Nephrocystin: Gene Expression and Sequence Conservation between Human, Mouse, and Caenorhabditis Elegans", J. Am. Soc. Nephrol. 11:270 [2000]	
	25	GAGNADOUX et al., Pediatr. Nephrol. 3, 50 [1989]	
	26	FILLASTRE et al., Clin Nephrol 5:14-19 [1976]	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.